Physician profile
Michael P Obrien
NPI 1598907453
$17,922.11
in general payments reported to CMS, 2019-2025
62 companies · $2,121 in 2025
The $2,121 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,646 · 2020: $2,200 · 2021: $2,509 · 2022: $2,264 · 2023: $3,170 · 2024: $3,012 · 2025: $2,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,302.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,302.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,540.42 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,417.99 | 2019-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $1,607.76 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $1,383.06 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,161.67 | 2019-2025 | Bexsero, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,110.95 | 2019-2025 | Jardiance |
| Amgen INC. | $746.69 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Astellas Pharma US INC | $677.46 | 2019-2025 | Veozah |
| Lilly USA, LLC | $576.03 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $558.24 | 2019-2025 | Gardasil 9, Rotateq, Vaxelis |
| Allergan, INC. | $510.88 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $330.50 | 2019-2024 | Xarelto, Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $314.94 | 2019-2023 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $302.39 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $274.82 | 2021-2025 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Obrien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.